We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $20.9M
1-Year Est. Return 195.52%
This Fund
S&P 500
This Quarter Est. Return
-4.5%
1 Year Est. Return
+195.52%
3 Year Est. Return
+318.83%
5 Year Est. Return
+369%
10 Year Est. Return
+2,361.28%
AUM
$16.7M
AUM Growth
-$2.59M
Cap. Flow
-$492K
Cap. Flow %
-2.94%
Top 10 Hldgs %
54.62%
Holding
39
New
–
Increased
3
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
HUMA icon
Humacyte
HUMA
+$156K
2
CMPS
Compass Pathways
CMPS
+$148K
3
MIST icon
Milestone Pharmaceuticals
MIST
+$114K

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$391K
2
VTYX
Ventyx Biosciences
VTYX
+$375K
3
NERV icon
Minerva Neurosciences
NERV
+$141K
4
MRSN
Mersana Therapeutics
MRSN
+$2.89K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$10.3B
$1.43M 8.57%
4,450
– –
MLTX icon
2
MoonLake Immunotherapeutics
MLTX
$1.32B
$1.26M 7.52%
67,500
– –
RPRX icon
3
Royalty Pharma
RPRX
$27.6B
$1.03M 6.14%
21,400
– –
MIST icon
4
Milestone Pharmaceuticals
MIST
$148M
$976K 5.83%
820,000
+65,000
+9% +$114K
GERN icon
5
Geron
GERN
$983M
$861K 5.15%
578,000
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.8B
$841K 5.03%
36,000
– –
ARDX icon
7
Ardelyx
ARDX
$986M
$771K 4.61%
128,650
– –
FENC icon
8
Fennec Pharmaceuticals
FENC
$413M
$691K 4.13%
112,434
– –
BNTC icon
9
Benitec Biopharma
BNTC
$435M
$660K 3.95%
62,000
– –
SRPT icon
10
Sarepta Therapeutics
SRPT
$2.28B
$620K 3.71%
28,500
– –
IRON icon
11
Disc Medicine
IRON
$3.17B
$518K 3.1%
8,100
– –
CUE icon
12
Cue Biopharma
CUE
$205M
$506K 3.03%
73,428
– –
CMPS
13
Compass Pathways
CMPS
$2.03B
$442K 2.64%
80,000
+22,000
+38% +$148K
BHVN icon
14
Biohaven
BHVN
$2.43B
$437K 2.61%
51,700
– –
LNTH icon
15
Lantheus
LNTH
$6.56B
$417K 2.49%
5,500
– –
JSPR icon
16
Jasper Therapeutics
JSPR
$23.3M
$407K 2.44%
465,000
– –
HUMA icon
17
Humacyte
HUMA
$192M
$394K 2.36%
650,000
+150,000
+30% +$156K
VTRS icon
18
Viatris
VTRS
$19.4B
$374K 2.24%
27,700
– –
KURA icon
19
Kura Oncology
KURA
$1.17B
$374K 2.24%
46,000
– –
BBIO icon
20
BridgeBio Pharma
BBIO
$15.4B
$371K 2.22%
5,000
– –
DYN icon
21
Dyne Therapeutics
DYN
$4.87B
$326K 1.95%
18,000
– –
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$397M
$308K 1.84%
86,000
– –
PCRX icon
23
Pacira BioSciences
PCRX
$1.03B
$305K 1.82%
13,500
– –
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.8B
$287K 1.71%
9,100
– –
MLYS icon
25
Mineralys Therapeutics
MLYS
$2.3B
$284K 1.7%
10,500
– –
1
2

Similar funds

SCM
Stadium Capital Management New Canaan, Connecticut $21M AUM 6.45% 1-Year Est. Return
MPW
MGO Private Wealth Irvine, California $20.7M AUM 18.57% 1-Year Est. Return
FS
Financially Speaking Greenwood Village, Colorado $20.6M AUM 16.79% 1-Year Est. Return
VAM
Vazirani Asset Management New York $20.3M AUM 79.33% 1-Year Est. Return
SPC
Stone Point Capital Greenwich, Connecticut $21.7M AUM 48.55% 1-Year Est. Return
SCM
Semanteon Capital Management Newton, Massachusetts $22.2M AUM 53.69% 1-Year Est. Return
HIIL
HS Investments III Ltd St. Peter Port $22.3M AUM
PMAM
Penn Mutual Asset Management Conshohocken, Pennsylvania $19.5M AUM 3.07% 1-Year Est. Return

Lion Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Lion Point Capital held 39 positions worth $16.7M, down 13% from $19.3M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Lion Point Capital's Q1 2026 filing shows 3 increased and 4 closed positions. The largest sale was Day One Biopharmaceuticals, an estimated $391K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lion Point Capital added most to Humacyte in Q1 2026, an estimated $156K increase.
  • Lion Point Capital fully exited Day One Biopharmaceuticals in Q1 2026, selling an estimated $391K.
  • Lion Point Capital's ten largest holdings make up 55% of its $16.7M portfolio in Q1 2026.
  • Lion Point Capital opened 0 new positions and closed 4 in Q1 2026.
  • Lion Point Capital's portfolio value fell 13% quarter-over-quarter to $16.7M.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.